Fundraising FoxSino Biopharmaceutical
Corporate VCBeijing · Seed · 11 people tracked
Find your way into Sino Biopharmaceutical
Sign up to see every warm intro you have to Sino Biopharmaceutical
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Sino Biopharmaceutical team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Sino Biopharmaceutical is an innovation- and R&D-driven Chinese pharmaceutical group operating the full value chain of innovative drugs, biologics and high-end generics, with leadership across oncology, liver and cardiovascular-metabolic, respiratory and autoimmune, and surgical and analgesic therapeutic fields. Listed on the Hong Kong Stock Exchange since 2000 (01177), it operates core drug R&D and production bases in Beijing, Shanghai, Guangzhou, Nanjing and Lianyungang. Its subsidiaries include Chia Tai Tianqing and Beijing Tide, while LaNova Medicines and Hygeia pursue source innovation. With a global R&D team of over 2,900, it has built cutting-edge platforms spanning bispecifics, ADC, PROTAC and oligonucleotides, pursuing innovation through in-house development, international partnerships and overseas licensing.
Source: firm website, verified Oct 2, 2026.
Team · 11 people
from the firm's websiteA co-founder of Sino Biopharmaceutical, now senior vice chairman and executive director, with over thirty years of experience investing in and managing China's pharmaceutical industry; chairman of several Chia Tai pharmaceutical subsidiaries.
A co-founder of Sino Biopharmaceutical and currently vice chairman and executive director; born 1964, holds an MBA from Peking University's Guanghua School and is a clinical physician with extensive pharmaceutical management and investment experience.
Joined the company in April 2015 as an independent non-executive director, chairman of the remuneration committee and member of the nomination committee.
Joined the company in December 2020 as an independent non-executive director and member of the audit and nomination committees; a physician holding honors including the Gold Bauhinia Star and JP.
Became Chairman of Sino Biopharmaceutical in 2015 and Vice Chairman of the Chia Tai Pharmaceutical Group; a Wharton School graduate who has been named eight times to Forbes' China outstanding businesswomen list and selected for Bloomberg Businessweek's 2024 figures of the year.
Executive director since 2019 and CEO of Sino Biopharmaceutical since 2022, also chairman of Chia Tai Tianqing and Beijing Tide; holds a Wharton economics degree and a management master's from Tsinghua's Schwarzman College.
Executive director and senior vice president responsible for the group's M&A and financing work and acting as company spokesman; a University of Hong Kong industrial engineering graduate who joined the group in 1995.
Independent non-executive director and chairman of the audit committee, and member of the remuneration and nomination committees.
Joined the company in June 2026 as an independent non-executive director and member of the audit, remuneration and nomination committees.
Joined the company in June 2026 as an independent non-executive director and member of the audit committee.
Joined the company in April 2015 as an independent non-executive director and member of the audit, remuneration and nomination committees.
Frequently asked questions
- What stage does Sino Biopharmaceutical invest at?
- Sino Biopharmaceutical invests at the Seed stage.
- What sectors does Sino Biopharmaceutical focus on?
- Sino Biopharmaceutical focuses on Biotech.
- Where is Sino Biopharmaceutical located?
- Sino Biopharmaceutical is headquartered in Beijing, CN.
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.